KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications

@article{Italiano2009KRASAB,
  title={KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications},
  author={PhD Antoine Italiano and Isabelle Hostein and PhD Isabelle Soubeyran and Thibault Fabas MSc and Daniel Benchimol and S. F. Kasun A. E. Evrard and Jean Gugenheim and Yves B{\'e}couarn and R. Brunet and Marianne Fonck and {\'E}ric François and Marie-Christine Saint-Paul and PhD Florence Pedeutour PharmD},
  journal={Annals of Surgical Oncology},
  year={2009},
  volume={17},
  pages={1429-1434}
}
KRAS and BRAF mutations in primary colorectal tumors (PT) are predictive of nonresponse to anti–epidermal growth factor receptor (EGFR) antibodies in patients with metastatic colorectal cancer (mCRC). The question of primary resistance to anti-EGFR treatment as a result of the presence of KRAS or BRAF mutations only in metastases has been raised but not resolved. We analyzed the mutational status of KRAS and BRAF in 64 new patients with mCRC and performed a systematic review of published data… CONTINUE READING
58 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…